Development of full human monoclonal Ab to human TRAIL-Rs for tumor therapy
10.11904/j.issn.1002-3070.2014.04.012
- VernacularTitle:全人源抗 TRAIL -R1／-R2单克隆抗体肿瘤治疗的研究进展
- Author:
Weijiao ZONG
;
Fengliang LU
;
Ye LIU
;
Aishun JIN
- Publication Type:Journal Article
- Keywords:
TRAIL;
TRAIL receptors;
Human mAb;
Tumor therapy
- From:
Practical Oncology Journal
2014;(4):344-348
- CountryChina
- Language:Chinese
-
Abstract:
Monoclonal antibodies(mAbs)to human TRAIL receptors(TRAIL-Rs)have been developed in tumor targeted therapy and currently used in clinical Ⅰ~Ⅳtrials.MAbs can bind death-receptors(TRAIL-R1 and TRAIL-R2)and then results in formation of the death inducing signaling complex (DISC)and apoptosis of tumor cells.TRAIL -Rs mAbs have become one of the research and development hotspots of anti -tumor drugs.These mAbs have achieved remarkable results in combination with radio -or chemo-therapy drugs or oth-er agents and immunotherapy in the treatment of tumor and offer a new therapeutic strategy for clinical tumor treatment.
